Advertisement

Topics

Acceleron to Host Research and Development Day on September 19, 2017

07:00 EDT 12 Sep 2017 | Businesswire

- Acceleron’s senior management team and external experts to present clinical development programs and preclinical research efforts -

- Live conference call and webcast scheduled for 8:00 a.m. EDT on September 19th

Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will webcast a live presentation from its Research and Development (R&D) Day on Tuesday, September 19, 2017. The event will take place from 8:00 a.m. to 12:00 p.m. EDT in New York City.

Members of the Acceleron leadership team will discuss the R&D strategy, long-term vision for the Company, and its clinical development programs across a range of disease areas, including neuromuscular disease and hematology. External experts, along with Acceleron, will provide insight into the current treatment of myelodysplastic syndromes (MDS), beta-thalassemia, and neuromuscular diseases. The Company will also present its latest preclinical research in a new therapeutic area of interest.

Guest external speakers include:

  • Maria Domenica Cappellini, M.D., Director of the Department of Clinical Sciences, Director of the Unit of Internal Medicine, University of Milan, Italy
  • David Steensma, M.D., Senior Physician, Dana-Farber Cancer Institute, Associate Professor of Medicine, Harvard Medical School
  • Martin Childers, D.O., Ph.D., Professor of Rehabilitation Medicine, Co-Director, MDA Clinic, University of Washington, Co-Director, Institute for Stem Cell and Regenerative Medicine

Conference Call and Webcast

The live webcast will be accessible under "Events & Presentations" in the Investors/Media page of the Company's website at www.acceleronpharma.com.

Individuals can participate in the conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and refer to "Acceleron 2017 R&D Day."

The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body's ability to rebuild and repair its own cells and tissues. The Company's lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene. Acceleron is also advancing its ACE-083 clinical program in the field of neuromuscular disease, and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Vice President, Investor Relations and Corporate Communications
or
Candice Ellis, 617-649-9226
Manager, Investor Relations and Corporate Communications
or
Media:
BMC Communications
Brad Miles, 646-513-3125

NEXT ARTICLE

More From BioPortfolio on "Acceleron to Host Research and Development Day on September 19, 2017"

Quick Search
Advertisement
 

Relevant Topics

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...